HOUSTON, TX--(Marketwire - Oct 23, 2012) - Idera, a leading provider of application and server management solutions, today demonstrated its strong commitment to the PowerShell community by making its ...
HOUSTON--(BUSINESS WIRE)--Idera, a leading provider of application and server management solutions, today announced the acquisition of Uptime Software Inc., a leading provider of IT systems monitoring ...
Shares of Idera Pharmaceuticals (NASDAQ: IDRA) are down around 15% year to date. And that's a good thing, relatively speaking: The clinical-stage biotech's stock was down by more than 55% just a few ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to ...
Idera Pharmaceuticals’ TLR9 agonist has failed to improve on Yervoy in a phase 3 melanoma trial. The miss on the objective response rate endpoint sent shares in Idera down 55%, but the biotech is yet ...
HOUSTON—May 23, 2019—Idera, Inc. (“Idera” or “the Company”), parent company of global B2B software productivity brands, today announced it will receive a new minority investment from Partners Group, a ...
Shares plunge in response to the announcement of a secondary share offering. The clinical-stage biopharma stated that it plans to raise up to $50 million through this common stock offering. Given that ...
Positive early-stage trial results boost excitement for IMO-8400. So what: Idera Pharmaceuticals is a clinical-stage company that is researching cancer therapies that work by targeting specific ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the presentation of preclinical data of its novel gene-silencing oligonucleotide (GSO) technology ...
EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. “2021 represents a ...
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results